CARDIOVASCULAR DRUGS AND THERAPY

Scope & Guideline

Pioneering the future of cardiovascular pharmacology.

Introduction

Delve into the academic richness of CARDIOVASCULAR DRUGS AND THERAPY with our guidelines, detailing its aims and scope. Our resource identifies emerging and trending topics paving the way for new academic progress. We also provide insights into declining or waning topics, helping you stay informed about changing research landscapes. Evaluate highly cited topics and recent publications within these guidelines to align your work with influential scholarly trends.
LanguageEnglish
ISSN0920-3206
PublisherSPRINGER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1987 to 2024
AbbreviationCARDIOVASC DRUG THER / Cardiovasc. Drugs Ther.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressVAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS

Aims and Scopes

The journal "Cardiovascular Drugs and Therapy" focuses on the pharmacological aspects of cardiovascular diseases and therapies, emphasizing the efficacy, safety, and mechanisms of various cardiovascular drugs. It serves as a critical platform for disseminating research findings that explore drug interactions, treatment outcomes, and innovative therapeutic strategies in the field of cardiovascular medicine.
  1. Pharmacotherapy in Cardiovascular Diseases:
    The journal discusses various pharmacological treatments for cardiovascular diseases, including antiplatelet agents, anticoagulants, lipid-lowering drugs, and antihypertensives, analyzing their efficacy, safety, and clinical implications.
  2. Clinical Trials and Meta-analyses:
    It publishes results from clinical trials and meta-analyses that evaluate the effectiveness of new and existing cardiovascular therapies, providing evidence-based insights for clinicians and researchers.
  3. Mechanisms of Cardiovascular Drugs:
    Research on the underlying mechanisms of action of cardiovascular drugs is a focus area, exploring how these drugs interact at the molecular and cellular levels to influence cardiovascular health.
  4. Innovative Therapeutic Strategies:
    The journal highlights novel approaches to cardiovascular treatment, including the development of new drug formulations, combination therapies, and the use of genetic and biomarker information to tailor treatments.
  5. Real-World Evidence and Pharmacovigilance:
    It emphasizes the importance of real-world data and pharmacovigilance studies in understanding the long-term safety and effectiveness of cardiovascular therapies, informing clinical practice.
The journal "Cardiovascular Drugs and Therapy" has identified several emerging trends and themes that reflect the evolving landscape of cardiovascular research and therapy. These topics are gaining traction and are likely to shape future research directions.
  1. Precision Medicine in Cardiovascular Therapy:
    There is a growing focus on precision medicine approaches, including pharmacogenomics, that tailor cardiovascular treatments based on individual genetic and molecular profiles to enhance efficacy and safety.
  2. Role of SGLT2 Inhibitors:
    SGLT2 inhibitors have become a significant area of research, with numerous studies exploring their cardiovascular benefits beyond glycemic control, particularly in heart failure and renal protection.
  3. Anticoagulation Strategies in Atrial Fibrillation:
    Research into optimizing anticoagulation strategies for atrial fibrillation patients is trending, particularly regarding the comparative effectiveness of direct oral anticoagulants versus traditional therapies.
  4. Cardiovascular Impacts of Diabetes Medications:
    The intersection of diabetes management and cardiovascular health is increasingly prominent, with studies examining the cardiovascular effects of GLP-1 receptor agonists and other diabetes medications.
  5. Long-term Outcomes of Cardiovascular Interventions:
    There is an emerging emphasis on the long-term outcomes of various cardiovascular interventions, including surgical and catheter-based procedures, highlighting the importance of sustained patient follow-up.

Declining or Waning

While many areas continue to thrive, certain themes in the journal "Cardiovascular Drugs and Therapy" have shown a declining interest or frequency of publication. These waning scopes may reflect shifts in research priorities or advancements in the field that have rendered some topics less relevant.
  1. Traditional Antihypertensive Therapies:
    There appears to be a reduction in studies focusing solely on traditional antihypertensive medications, as newer classes of drugs and combination therapies gain prominence in clinical practice.
  2. Single-Agent Studies:
    Research focused exclusively on single-agent therapies is declining, with a noticeable shift towards combination therapies and multi-drug regimens that reflect contemporary clinical practice.
  3. Pharmacokinetics of Established Drugs:
    There is less emphasis on the pharmacokinetics of well-established cardiovascular drugs, as research increasingly prioritizes new therapeutic agents and innovative treatment strategies.
  4. Animal Model Studies:
    The prevalence of studies using traditional animal models to evaluate drug efficacy is decreasing, potentially due to a growing focus on human clinical trials and translational research.
  5. Generalized Risk Factor Studies:
    Research that broadly addresses cardiovascular risk factors without a direct link to specific therapeutic interventions is diminishing, as the emphasis shifts towards targeted therapeutic approaches.

Similar Journals

VASCULAR PHARMACOLOGY

Exploring the frontiers of vascular pharmacotherapy.
Publisher: ELSEVIER SCIENCE INCISSN: 1537-1891Frequency: 12 issues/year

Vascular Pharmacology, published by Elsevier Science Inc, is a leading journal in the fields of pharmacology and molecular medicine, dedicated to advancing our understanding of vascular biology and therapeutic interventions. With an impressive impact factor reflecting its significant contribution to the scientific community, this journal seeks to publish ground-breaking research that elucidates the molecular mechanisms underlying vascular function and disease, as well as the pharmacological impact of new therapeutic agents. The journal operates under a dual access model, allowing for both subscription and open access options, ensuring that vital research is accessible to a wide audience. As of 2023, it holds a prestigious position in the Q1 category for pharmacology and ranks well in molecular medicine and physiology, reflecting its high quality and relevance. Whether you are a researcher, clinician, or student, Vascular Pharmacology serves as an essential resource to stay at the forefront of cardiovascular pharmacotherapy and vascular biology.

DRUGS IN R&D

Leading the charge in pharmacology and toxicology advancements.
Publisher: SPRINGER INT PUBL AGISSN: 1174-5886Frequency: 4 issues/year

DRUGS IN R&D is a premier open access journal dedicated to advancing the field of pharmacology and drug development. Published by Springer International Publishing AG, this journal has been a valuable resource for researchers and professionals since its inception in 1999, contributing critical insights into the pharmacological sciences. With an impressive Impact Factor reflecting its significance, DRUGS IN R&D ranks in the Q2 quartile for Pharmacology, according to 2023 metrics, and ranks #151 out of 313 in the field of pharmacology and toxicology on Scopus. This journal offers an open access format, ensuring high visibility and accessibility of research findings to a global audience, supporting the intrepid pursuit of knowledge in drug research and development. By facilitating comprehensive discussions and innovative research findings, DRUGS IN R&D plays a crucial role in shaping the future landscape of pharmacological studies and advancements.

CARDIOVASCULAR RESEARCH

Exploring the complexities of cardiovascular health.
Publisher: OXFORD UNIV PRESSISSN: 0008-6363Frequency: 18 issues/year

CARDIOVASCULAR RESEARCH, published by Oxford University Press, is a premier academic journal dedicated to the evolving field of cardiology and cardiovascular medicine. With a remarkable impact factor reflecting its significant contribution to the scientific community, this journal maintains a Q1 ranking in both Cardiology and Physiology categories, demonstrating its commitment to publishing high-quality research that influences clinical practices and healthcare outcomes. Established in 1967, the journal has consistently provided a platform for innovative studies and reviews, aiming to advance our understanding of cardiovascular physiology and pathology. Researchers, professionals, and students will find published articles crucial for their work, as the journal covers a broad spectrum of topics including molecular biology, genetics, and clinical studies. While currently not offering open access options, CARDIOVASCULAR RESEARCH remains accessible through institutional and individual subscriptions, ensuring that the latest findings are available to those in the cardiovascular science community.

CIRCULATION JOURNAL

Connecting Global Insights in Cardiology and Medicine.
Publisher: JAPANESE CIRCULATION SOCISSN: 1346-9843Frequency: 12 issues/year

CIRCULATION JOURNAL, published by the Japanese Circulation Society, stands as a premier platform for cutting-edge research in the fields of Cardiology and Cardiovascular Medicine. With an impressive impact factor placing it in the Q1 quartile for both cardiology and general medicine, this journal is essential for researchers and practitioners seeking to stay at the forefront of cardiovascular science. The journal's accessible open access options ensure that groundbreaking studies are widely disseminated, reflecting its commitment to advancing medical knowledge and improving patient care. Since its inception in 1996, CIRCULATION JOURNAL has fostered a global dialogue on vital cardiovascular issues, making it a vital resource for academics, healthcare professionals, and students alike. With its base in Tokyo, Japan, the journal not only highlights regional advancements but also contributes significantly to the global medical community.

PROGRESS IN CARDIOVASCULAR DISEASES

Elevating Standards in Cardiovascular Research
Publisher: W B SAUNDERS CO-ELSEVIER INCISSN: 0033-0620Frequency: 6 issues/year

PROGRESS IN CARDIOVASCULAR DISEASES is a leading journal in the field of cardiology and cardiovascular medicine, published by W B SAUNDERS CO-ELSEVIER INC. With an impressive impact factor that places it in the esteemed Q1 quartile of its category, this journal ranks among the top 32 out of 387 journals in its field, positioning itself in the 91st percentile. Since its inception in 1958 and continuing until 2024, it has been a prolific source of cutting-edge research, reviews, and clinical insights that contribute significantly to the understanding and treatment of cardiovascular diseases. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that all published content meets the highest standards of scientific excellence. As a key resource for researchers, practitioners, and students alike, PROGRESS IN CARDIOVASCULAR DISEASES serves as an indispensable tool for advancing knowledge and practice in cardiovascular health.

Journal of the Practice of Cardiovascular Sciences

Exploring New Frontiers in Cardiovascular Sciences
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 2395-5414Frequency: 3 issues/year

Journal of the Practice of Cardiovascular Sciences, published by Wolters Kluwer Medknow Publications, is an esteemed Open Access journal dedicated to advancing knowledge in the field of cardiovascular health. With its ISSN 2395-5414 and E-ISSN 2454-2830, the journal serves as a vital platform for researchers, healthcare professionals, and students to disseminate and access high-quality studies, innovations, and practical applications related to cardiovascular sciences. Established in 2015 as an Open Access journal, it promotes widespread sharing of insights to enhance cardiovascular practices and address contemporary challenges in the field. As part of a reputable publishing group, the journal is poised for growth and impact, contributing significantly to the ongoing dialogue in cardiovascular research and clinical practice.

International Journal of Cardiology

Connecting Researchers and Clinicians to Shape Heart Health
Publisher: ELSEVIER IRELAND LTDISSN: 0167-5273Frequency: 24 issues/year

The International Journal of Cardiology is a premier publication in the field of Cardiology and Cardiovascular Medicine, published by Elsevier Ireland Ltd. With an impressive impact factor and ranked in the top quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and scholars committed to advancing cardiovascular health. Founded in 1981, the journal has been pivotal in disseminating significant findings, with a wide-ranging scope that includes original research, reviews, and clinical studies aimed at improving patient outcomes and understanding heart diseases. Its robust ranking of #73 out of 387 in Scopus ensures that it remains a leading platform for impactful cardiovascular research. While currently not an open-access publication, the journal's commitment to quality and relevance makes it an essential reference point within an ever-evolving medical landscape. For those engaged in cardiovascular research, the International Journal of Cardiology is not just a journal; it's an indispensable source of knowledge shaping the future of heart health.

Cardiology in Review

Pioneering reviews that shape cardiovascular care.
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 1061-5377Frequency: 6 issues/year

Cardiology in Review, published by Lippincott Williams & Wilkins, is a prominent journal focused on advancing the field of cardiology and cardiovascular medicine. With a history of publication spanning from 1995 to 2024, the journal serves as an essential resource for researchers, healthcare professionals, and students alike, offering in-depth reviews and analyses on the latest developments, clinical practices, and research findings in cardiology. Despite being a traditional print journal, it maintains a commendable Q2 ranking in both cardiology and miscellaneous medicine categories as of 2023, reflecting its influence and rigor in the academic community, with a Scopus rank of #132 out of 387 in its field, placing it in the 66th percentile. The journal aims to bridge the gap between clinical practice and emerging research, promoting a deeper understanding and integration of innovative strategies in cardiovascular care. With its commitment to high-quality scholarship, Cardiology in Review remains a vital conduit for knowledge and dialogue within the evolving landscape of cardiovascular health.

European Journal of Preventive Cardiology

Transforming the future of heart health through research.
Publisher: OXFORD UNIV PRESSISSN: 2047-4873Frequency: 18 issues/year

The European Journal of Preventive Cardiology, published by Oxford University Press, is a leading international journal dedicated to the field of cardiology and cardiovascular medicine. With an impact factor that underscores its prestige—ranking in the top quartile (Q1) of both cardiology and epidemiology categories—the journal serves as a critical resource for researchers and practitioners seeking to advance their understanding of preventive strategies in cardiovascular health. Since its inception in 1999, it has provided a platform for high-quality research and reviews that address the epidemiology of cardiovascular diseases, risk factor management, and innovative prevention methodologies. Notably, it currently ranks #21 out of 387 in Medicine - Cardiology and #13 out of 148 in Medicine - Epidemiology according to Scopus, highlighting its influential position in these essential biomedical fields. The journal also provides open access options, allowing both readers and authors the opportunity to engage with groundbreaking research and enhance the dissemination of knowledge. With a commitment to excellence, the European Journal of Preventive Cardiology is an invaluable asset for those dedicated to the prevention of cardiovascular diseases.

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Leading the way in cardiovascular pharmacological research.
Publisher: SAGE PUBLICATIONS INCISSN: 1074-2484Frequency: 6 issues/year

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.